Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligufalimab and Cadonilimab in Advanced Hepatobiliary Cancers
NCT06789848Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Feb 2025
- Primary completion
- May 2029
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ligufalimab and cadonilimab in hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) (2 cohorts), sponsored by UT Southwestern Medical Center. Primary endpoint: Objective Response Rate up to 24 months. Started Feb 2025; status: recruiting.
02
Drugs
ligufalimabcadonilimab
03
Conditions
hepatocellular carcinoma (HCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06789848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789848.